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LESS INVASIVE AND COST-
EFFECTIVE
ALTERNATIVE FOR DRAINAGE
OF PLEURAL EFFUSION
To the Editor:
It was with great interest that I read
a response letter by Asopa and Patel1
to an article by Chetty and colleagues.2
Their article describes the safe use of
a Bonanno catheter for drainage of
a pleural effusion. Asopa and Patel
called for modifications to the catheter
before itwas considered for general use
after an incident at their center inwhich
the left ventricle was inadvertently
pierced during catheter insertion.
Traditionally, the Seldinger tech-
nique has been used to insert a pigtail
drain into the intercostal space to allow
the safe drainage of a pleural effusion.3
Many risks and technical difficulties
come with the use of this technique.
Often the needle is misplaced when
the aspiration syringe is being re-
moved, leading to drain insertion
outside the chest cavity or indeed the
needle being advanced into the heart
or large vessels.4
The use of the Bonanno catheter as
described by Chetty and associates2
is an innovative use of a suprapubic
catheter and, in my experience, a sim-
ple and safe way to insert a chest drain.
The technique is fully described in
their article, and there are several steps
that ensure that the procedure is
carried out as safely as possible and
the complication risk is minimized.
Asopa and Patel1 believed that theThe Journallength of the catheter and the lack of
external markings caused the method
to become unsafe compared with the
Seldinger technique. I disagree. If the
method of insertion laid out clearly
and concisely in the article by Chetty
and associates is followed carefully,
complications can be avoided. It is rec-
ommended that during local anesthetic
infiltration, the parietal pleura be
breached and a test aspiration carried
out. This allows the operator to feel
and see how far the catheter will
need to be advanced; the test will en-
sure that the effusion is present at
that intercostal level and that it is large
enough to be drained safely. If there
are any problems with this test aspira-
tion, the procedure should be aban-
doned. Second, when advancing the
catheter, one should be aspirating all
the time so that as soon as the pleura
is breached and the effusion is aspi-
rated, it is apparent that the catheter
is in the cavity and the operator can
stop advancing the needle. The tech-
nique is then extremely simple; the
catheter is advanced while the needle
is being held still, similar to the tech-
nique for venous cannulation, until
the catheter has been fully inserted.
I see no reason why one should lose
track of how far the needle has been ad-
vanced. If the operator is able to aspirate
fluidwith a local anesthetic needle, then
the distance the catheter and tracer need
to be advanced will be relatively small.
If the operator is aspirating the entire
time, then the equipment should not
be advanced beyond the effusion and
into the heart or large vessels.
I appreciate the concerns that Asopa
and Patel have expressed, and indeed
markings on the catheter may prove
to be helpful to some, but if Chetty
and colleagues’ comprehensive guid-
ance is followed, no problems should
be encountered.
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OF ISCHEMIC STATES
PREVENTS MYOCARDIAL
INJURY, ATTENUATING THE
OXIDATIVE AND
INFLAMMATORY RESPONSE
To the Editor:
We read with great interest the re-
cent article by Abdel-Rahman and
colleagues1 on the favorable effect of
‘‘hypoxic reoxygenation’’ in the atten-
uation of myocardial ischemia–reper-
fusion injury after cardioplegic arrest.
The importance of progressive oxygen
re-entry into ischemic tissues has been
shown since 2001 in the brains of a por-
cine model of cardiac arrest.2,3 The fa-
vorable effect of the strategy was
documented through better overall
neurological performance, less lipid
peroxidation,2 and attenuation of the
brain morphologic changes.3 Because
of malondialdehyde (MDA) increase,
oxidative stress has been theoretically
implicated, thought not confirmed by
the measurement of reactive oxygen
species (ROS).
With regard to the current study, 3
comments are to be addressed. First,
the authors deduced oxidative myocar-
dial injury by determining MDA
concentrations in coronary sinus blood
without comparative reference MDA
concentrations at the distal site. Never-
theless, ROS seem to be directly cardi-
otoxic, independent of the site of theiry c Volume 139, Number 5 1357
Letters to the Editorproduction. In fact, normoxemic
reperfusion of a distal ischemic organ
(eg, the intestine) has been shown to
cause myocardial injury that was
prevented with progressive oxygen
re-entry during reperfusion.4
Second, in the above studies, similarly
to the current one, with the exception
of MDA measurement, the favorable
effect of hypoxemic reperfusion was
not substantiated by direct indices of
oxidative stress alterations, such as
ROS measurement. ROS and cytokines
were recently assessed in a model of
hypoxemic resuscitation of hemorrhagic
shock in rabbits and found to be particu-
larly diminished compared with those
seen in the standard resuscitation mode
of clinical practice.5 The weakening
effect on cytokine production is an
additional important achievement of
hypoxemic resuscitation because these
mediators lead to post–ischemia–reper-
fusion inflammatory injury.
Third, the authors have repetitively
used erroneously the term ‘‘hypoxic
reoxygenation’’ instead of ‘‘hyper-
oxic reoxygenation’’ to describe
PaO2 values of 250 to 350 mm Hg,
which is usually applied in the clini-
cal setting. Furthermore, we consider
even more accurate the term ‘‘hyper-
oxemic’’ because it describes higher
arterial oxygen content largely and
easily modifiable by fraction of in-
spired oxygen changes; in contrast,
the term ‘‘hyperoxic’’ describes tis-
sue oxygen concentration dependent
on addition to hemodynamic parame-
ters. Correspondingly, the other treat-
ment branch is represented by gradual
reoxygenation by means of an initial
‘‘hypoxemic’’ instead of ‘‘hypoxic’’
period.
Our published data support the
findings of Abdel-Rahman and col-
leagues1 regarding the principal idea
of the strategy for the prevention of re-
perfusion injury,2-4 the restoration of
hemodynamic parameters,4,5 and the
attenuation of oxidative stress.2–5 Ad-
ditionally, these data provide a further
insight into the potentially protective
role of this strategy through the atten-1358 The Journal of Thoracic anduation of the inflammatory response
during reperfusion.5
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STATINS: ANOTHER
PLEIOTROPIC BENEFIT?
To the Editor:
We read with interest the recent trial
by Hillis and associates,1 demonstrat-
ing that hyperuricemia was associated
with poorer survival after coronary ar-
tery bypass grafting (CABG), indepen-
dently of other risk factors, including
the European System for Cardiac Op-
erative Risk Evaluation (Euro-
SCORE). Also, this increased risk
was particularly evident among pa-
tients with levels in the upper quartile.
It has been showed that treatment
with statins2 can reduce serum uricCardiovascular Surgery c May 2010acid (SUA) levels; thus they would
have an additional beneficial effect
apart from that derived for lowering
low-density lipoprotein cholesterol
(LDL-c) levels. However, little infor-
mation is available about the effects
of high doses of statins on the SUA
levels. The present study focuses on
the possible effect of using a high
dose of atorvastatin on SUA levels.
We therefore hypothesized that the
use of the highest dose of atorvastatin
(80 mg/day) in high-risk patients un-
der treatment with atorvastatin 40
mg/day would reduce SUA levels.
We studied 29 ‘‘high-risk’’ patients
(inclusion criteria: severe triple vessel
disease but rejected for bypass for ex-
tensive coronary disease, severe effort
angina after coronary artery bypass,
and premature coronary disease with
 3 risk factors) with an abnormal
lipid profile despite atorvastatin 40
mg/day at baseline and at 3 months af-
ter increasing the dose to 80 mg/day.
Baseline results in patients were com-
pared with those of 39 healthy con-
trols. The lipid profile, C-reactive
protein levels (CRP), SUA levels of
patients and controls, and the changes
after increasing doses of atorvastatin
are shown in Table 1, A and B. At base-
line, patients had higher levels of SUA
(P ¼ .036) compared with controls.
Follow-up was completed in a total
of 26 patients (2 patients withdrew
voluntarily from the study and 1 pa-
tient had no samples at 3 months). Af-
ter the dose of atorvastatin had been
increased, a significant decrease in
CRP (P ¼ .004) and SUA (P ¼ .018)
levels were detected among treated pa-
tients. Also, these reductions did not
show correlation with the changes of
lipid profile (cholesterol, triglycerides,
LDL-c, and high-density lipoprotein
cholesterol). No adverse effects were
observed in any patients.
The present study shows that in-
creasing doses of atorvastatin at 80
mg reduces SUA levels compared
with the 40-mg dose in high-risk pa-
tients with ischemic heart disease. Pre-
vious studies have shown that
